NewcelX Prices $1.35M Equity Financing NewcelX priced $1.35M on Apr 1, 2026 (Seeking Alpha). The micro-cap raise could extend runway ~3 months; investors should await filing with pricing and share count.

NewcelX Prices $1.35M Equity Financing: NewcelX priced $1.35M on Apr 1, 2026 (Seeking Alpha). The micro-cap raise could extend runway ~3 months; investors should await filing with pricing and share count. 👈 Read full analysis #NewcelX #EquityFinancing #Investment #MicroCap #FinanceNews

NewcelX and Eledon Pharmaceuticals Join Forces to Tackle Type 1 Diabetes A strategic collaboration between NewcelX and Eledon aims to innovate treatments for Type 1 Diabetes, integrating advanced immunotherapy and stem cell technology.

NewcelX and Eledon Pharmaceuticals Join Forces to Tackle Type 1 Diabetes #Type_1_Diabetes #Switzerland #Zurich #NewCelX #Eledon

NewcelX Strengthens Mazindol's Path with Major Publication and Strategic Advancements NewcelX Ltd. reinforces its position in the biopharmaceutical sector through a pivotal publication regarding Mazindol and its monetization strategies.

NewcelX Strengthens Mazindol's Path with Major Publication and Strategic Advancements #Switzerland #Zurich #Mazindol #NewCelX #Clinical_Drug_Investigation

NewcelX Prepares for Spring 2026 Conferences with Updated Corporate Strategies and Focus on Type 1 Diabetes Treatments NewcelX Ltd. has unveiled an updated corporate presentation ahead of significant investor conferences, placing emphasis on Type 1 Diabetes therapies and new expert additions.

NewcelX Prepares for Spring 2026 Conferences with Updated Corporate Strategies and Focus on Type 1 Diabetes Treatments #biotechnology #Switzerland #Zurich #Diabetes_Therapy #NewCelX

NewcelX Reports Promising Advances in Diabetes Treatment Using Advanced Biomaterials NewcelX Ltd. announces breakthrough findings in an international study, demonstrating potential for enhanced islet delivery in Type 1 Diabetes without immunosuppression.

NewcelX Reports Promising Advances in Diabetes Treatment Using Advanced Biomaterials #Switzerland #Biomaterials #Zurich #diabetes #NewCelX

NewcelX Welcomes Diabetes Expert Dr. Julien Boisdron to Scientific Advisory Board NewcelX Ltd. has announced the appointment of Dr. Julien Boisdron to its Scientific Advisory Board, enhancing its focus on diabetes therapies.

NewcelX Welcomes Diabetes Expert Dr. Julien Boisdron to Scientific Advisory Board #Switzerland #Zurich #IsletRx #NewCelX #Dr._Julien_Boisdron

NewcelX Announces DOXA Patent Application Publication in China: A Key Milestone for Neurology Innovations NewcelX Ltd. has published a crucial patent application in China for DOXA compounds, enhancing its global IP strategy in neurology and metabolic diseases.

NewcelX Announces DOXA Patent Application Publication in China: A Key Milestone for Neurology Innovations #Switzerland #Zurich #Neurology #NewCelX #DOXA

NewcelX Enhances Scientific Advisory Board With Leading Neurologist Jeremy Shefner NewcelX Ltd. has appointed renowned neurologist Jeremy Shefner to its Scientific Advisory Board, enhancing its focus on ALS and neuromuscular disorders.

NewcelX Enhances Scientific Advisory Board With Leading Neurologist Jeremy Shefner #ALS_Research #Switzerland #Zurich #NewCelX #Jeremy_Shefner

NewcelX Welcomes Prof. Tamir Ben-Hur to Its Scientific Advisory Board NewcelX Ltd. has announced the addition of Professor Tamir Ben-Hur to its Scientific Advisory Board, enhancing its expertise in neurodegenerative therapies.

NewcelX Welcomes Prof. Tamir Ben-Hur to Its Scientific Advisory Board #biotechnology #Switzerland #Zurich #NewCelX #Tamir_Ben-Hur

NewcelX CEO Addresses Shareholders: A Vision for Innovative Therapies Ahead In a recent letter, NewcelX CEO Ronen Twito outlines the company’s ambitious plans for the next 12 months, focused on breakthrough therapies for serious diseases.

NewcelX CEO Addresses Shareholders: A Vision for Innovative Therapies Ahead #biopharmaceuticals #Switzerland #Zurich #NewCelX #Ronen_Twito

NewcelX's Strategic Roadmap Update After Merger with NLS Pharmaceutics NewcelX shares key developments and strategic direction after merging with NLS Pharmaceutics, enhancing their biopharmaceutical capabilities.

NewcelX's Strategic Roadmap Update After Merger with NLS Pharmaceutics #Switzerland #ALS #NLS_Pharmaceutics #Zurich #NewCelX

NewcelX Emerges: A Major Merger in Biotechnology Industry The merger of NLS Pharmaceutics and Kadimastem marks a significant breakthrough in biotechnology, leading to the birth of NewcelX, focused on advanced therapies for neurodegenerative diseases.

NewcelX Emerges: A Major Merger in Biotechnology Industry #Switzerland #NLS_Pharmaceutics #Zurich #Kadimastem #NewCelX

NLS Pharmaceutics and Kadimastem Finalize Merger Conditions and New Listing Plans NLS Pharmaceutics and Kadimastem complete all necessary conditions for their merger and announce plans for listing on Nasdaq as NewCelX Ltd. after delisting from TASE.

NLS Pharmaceutics and Kadimastem Finalize Merger Conditions and New Listing Plans #Israel #NLS_Pharmaceutics #Zurich #Kadimastem #NewCelX

NLS Pharmaceutics and Kadimastem's Merger Gains Nasdaq Approval, Set for Closure by October 2025 NLS Pharmaceutics and Kadimastem have received Nasdaq approval for their merger, expected to close on October 30, 2025, reshaping the landscape of CNS therapies.

NLS Pharmaceutics and Kadimastem's Merger Gains Nasdaq Approval, Set for Closure by October 2025 #Switzerland #NLS_Pharmaceutics #Zurich #Kadimastem #NewCelX

NLS Pharmaceutics and Kadimastem to Create NewCelX Through Merger Approval NLS Pharmaceutics and Kadimastem successfully secure shareholder approval for their merger, establishing NewCelX as a Nasdaq-listed company focused on innovative therapies.

NLS Pharmaceutics and Kadimastem to Create NewCelX Through Merger Approval #Switzerland #NLS_Pharmaceutics #Zurich #Kadimastem #NewCelX

Kadimastem and NLS Pharmaceutics Announce SEC Clearance for Merger Completion Kadimastem and NLS Pharmaceutics have received SEC approval for their merger, paving the way for the establishment of NewCelX Ltd., focused on innovative therapies.

Kadimastem and NLS Pharmaceutics Announce SEC Clearance for Merger Completion #Switzerland #NLS_Pharmaceutics #Zurich #Kadimastem #NewCelX